Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To evaluate progression-free survival time of subjects treated with EMD 1201081 + cetuximab compared to cetuximab alone in cetuximab-naïve subjects with recurrent and/or metastatic SCCHN who have progressed on a cytotoxic therapy.
Inclusion criteria
- Recurrent/metastatic squamous cell cancer of the head and neck